The debate about life sciences regulation too often centres on the burden it imposes, rather than the value it creates.
In this thought leadership article, John Wilkinson OBE, Principal at MedTech Vision and former Director of Devices at the UK Medicines and Healthcare products Regulatory Agency, argues that regulatory capability can enable the safe introduction of new technologies, reduce unnecessary complexity and strengthen the UK’s attractiveness to investment, but that realising its potential requires more than well-crafted legislation.

The conventional view of regulation is that it is a drag on economic activity and should be stripped back. Of course, that is until a public health event occurs and there is a clamour for more regulation and a temptation to pillory the regulators. The truth, of course, is that regulation often grows incrementally and can become unhelpfully prescriptive in the wake of health incidents or perceived ‘scandals’. Such was the development of medical devices regulation in the wake of the PIP breast implant ‘scandal’ which was, in reality, simple fraud involving the use of unsuitable materials and falsified documentation.
In times of fiscal stress, the stripping away of regulatory capacity is easily done and has little immediate consequence as long as nothing goes wrong. It is a little like insurance; an expensive overhead until you need to claim and then the sense of regret at not keeping the premiums up is more than palpable. However, it is more than that.
Enabling innovation and reducing regulatory burden
Regulatory capability and capacity is a huge asset in an economy which sets out to lead in the life sciences sector. Regulatory innovation can serve two masters. The first, and most obvious, of these is that an ecosystem containing intelligent and focused people can develop regulation that enhances the safe introduction of new and innovative medical technologies. This does not often sit easily with established methods and requires the thoughtful development of new risk management tools and processes. Countries with regulatory capacity and the openness to change can become extremely attractive places to invest in and develop future global technologies.
The second, and less obvious, area where innovative regulatory capacity brings benefits is the very opposite to the ‘regulation is a drag on economic activity’ school of thought. Reducing regulatory burden without increasing risk to patients is a valuable but challenging activity which requires considerable intellectual and practical resource. It is no surprise that regulatory systems often settle for incremental rule-making which is reputationally less risky, rather than designing new, less complex, but more effective, methodologies.
The successful redesign of long-standing legislation and procedures is necessary, but is also fraught with risk. However, if this is not addressed, then we are faced with either increasing cost and burden with limited patient safety benefit, or the cutting of ‘red tape’ that has not been well evaluated and that leaves the public exposed to new risks. To an extent, the European Medical Device Regulation could be described as being currently caught in this tangle.
Building on the UK’s regulatory ecosystem
Life sciences regulatory capacity in the UK is an unrecognised and still under-exploited national asset. This asset is not confined to any one institution although, clearly, a national regulator like the Medicines and Healthcare products Regulatory Agency (MHRA) is a critical lynchpin. It is encouraging to see that the MHRA is seeing itself as an innovator and is staffing up for that challenge. It is also apparent that the Agency has recognised and understood the challenges of accessing sufficient intellectual capacity and bandwidth to respond to future technological challenges. Using expert networks is a great way for governments and regulators to bring expertise to the table, and the UK is very well positioned to deliver that expertise via initiatives such as the Centres of Excellence for Regulatory Science and Innovation (CERSIs). UK universities have a wealth of skills and knowledge which can be further exploited to ensure that the regulatory ecosystem continues to develop and prosper.
In addition to the academic dimension, we have world-leading conformity assessment bodies such as the British Standards Institution (BSI) and innovators such as Scarlet, who focus on the specific challenges associated with regulating software as a medical device. The network of conformity assessment bodies brings a wealth of technical expertise, as well as first-hand experience of the specific regulatory challenges faced by manufacturers globally. The relationship between regulators and conformity assessment bodies is a delicate one, in that the regulator effectively sub-contracts regulatory activity to these organisations, while at the same time supervising them. Collectively they have a huge opportunity to accelerate the evolution of regulation, but that interaction needs careful management and transparent governance in order to optimise it without compromising the integrity of either side.
Developing regulatory expertise
Another element of a successful regulatory ecosystem is access to a well-trained expert community. It is evident that, however well legislation is crafted, it counts for very little if there is a paucity of capable people to implement it. The UK has a strong infrastructure to support the ecosystem, including TOPRA, which provides top-class education ranging from introductory programmes for those making their first steps in regulatory affairs, to its renowned MSc programme (in conjunction with the University of Hertfordshire) and its continuing professional development (CPD) programmes. For medical devices in particular, this capability is vital in the absence of globally accepted professional career pathways, and represents another opportunity for the UK to deliver high-quality expertise which serves both the UK and the global community. It is no coincidence that the UK contributes heavily to the European and global capacity of leading regulatory personnel. Programmes such as those at TOPRA are a key driver and deserve widespread support and steering from leaders in the professional community.
It is also worth emphasising the importance of a competent and confident regulatory workforce as a critical asset. Less competent operators can take poorly formulated ideas to regulators who, if they themselves are inexperienced and lacking in confidence, merely refer applicants to guidance and ask for further clarification. Contrast this with the alternative, where highly competent operators take well refined proposals to regulators and have discussions that lead to clear outcomes and actions. The latter brings products to the market faster but, more importantly, in a safer and more effective, risk-managed manner. This leads to a win-win where all parties feel they have contributed to a successful outcome.
This scenario extends to the critical role of supporting and supervising clinical trials and investigations in the UK. The judgement and engagement of the excellent teams at the MHRA, aligned with the National Institute for Health Research (NIHR) and the broader NHS, make the UK the perfect environment for clinical research, but only if incentives are aligned across the whole system.
Turning capability into strategic advantage
In conclusion, I am an advocate for tactical investment in this critical strategic asset. This will not happen on its own and needs leading regulatory stakeholders to step up and lead in a collaborative manner. It is critical that the government fully grasps the importance of an enabling regulatory capability to support the delivery of any life sciences strategy. The UK community remains strong, despite the regulatory impact of exiting the EU system. Regulatory strategy that galvanises contributions from the regulatory community can address both the need to work on risk managing the introduction of new technologies (in particular the use of Artificial Intelligence), as well as innovating the regulatory system and the tools it has to keep us all safe.
We are already seeing the benefits of the CERSI network and MHRA leadership, but this needs to be translated into practical tools to create an attractive environment for technological innovators to operate in. A strategic leadership vehicle involving key stakeholders could help set both the innovation investment and regulatory simplification agendas and, in turn, allow the UK to be restored to its position as a global thought leader. The economic spin-offs from this would accelerate both inward investment and the export of services associated with centres of excellence in regulatory affairs. This turns the overused paradigm that regulation is a dragging anchor on the progress of economic endeavour entirely on its head.
























